Figure 2.
Frequency of prognostically relevant molecular and cytogenetic subgroups of AML arising in younger adults.
Frequencies of the various entities specified in Table 2 are based on a synthesis of published data 9,16,19,–25 and analysis of adults with AML entered into the MRC AML10 and 12 trials.6